Drawing on the film Wonder, this article examines how a narrative of community acceptance offers sustaining relationships for people with unusual facial appearance.
AMA J Ethics. 2019;21(11):E1003-1008. doi:
10.1001/amajethics.2019.1003.
Considering chronic opioid use when planning elective surgery would likely enhance team communication, decrease stigma, and facilitate care transitioning and long-term planning.
AMA J Ethics. 2020;22(8):E664-667. doi:
10.1001/amajethics.2020.664.
Countering the prevailing thought that more medical testing and treatment is always better can be achieved by creating a forum for open discussion of costs and value to prevent patient harm from overuse.
AMA J Ethics. 2015;17(11):1079-1081. doi:
10.1001/journalofethics.2015.17.11.mnar1-1511.
Joel A. DeLisa, MD, MS and Jacob Jay Lindenthal, PhD, DrPH
Research on experiences of practicing physicians who have disabilities could help medical schools counsel applicants and increase enrollment among students with disabilities. This can ultimately improve care for patients with disabilities.
AMA J Ethics. 2016;18(10):1003-1009. doi:
10.1001/journalofethics.2016.18.10.stas1-1610.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dr Emma Cooke joins Ethics Talk to discuss her article, coauthored with Dr Holland Kaplan: “How Should Technology-Dependent Patients’ Care Be Managed Collaboratively to Avoid Turfing?”